Targeting KIT prevents brain arteriovenous malformations driven by ALK1-deficient angiogenic endothelial cells
Journal of Clinical Investigation · 2026
DOI: 10.1172/jci197587 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Investigation, 2026. Verfasst von Elise Drapé und 16 weiteren Autor:innen. Beteiligte Einrichtung: Département De Pharmacologie Et De Physiologie, Faculté de médecine, Université de Montréal, Montréal, Centre De Recherche CHU St. Justine, Montréal,…. Hauptthemen laut MEDLINE: Endothelial Cells, Intracranial Arteriovenous Malformations, Activin Receptors, Type II, Proto-Oncogene Proteins c-kit. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Institutes of Health Research.
Abstract (Originalsprache)
Hereditary hemorrhagic telangiectasia type 2 (HHT2), caused by mutations in ACVRL1 (also known as ALK1 ), is characterized by brain arteriovenous malformations (bAVMs), abnormal artery–vein connections for which treatment options remain limited. Despite evidence of endothelial cell (EC) heterogeneity, its role in bAVM pathogenesis remains poorly defined. Using EC-specific inducible Alk1 -knockout mice ( Alk1iECKO ) and regionally resolved single-cell RNA sequencing, we showed that loss of ALK1 signaling induces bAVMs predominantly in the perineural vascular plexus. This process is driven by the emergence of a KIT + angiogenic EC population with human AVM-like transcriptional features, including tip cell markers and activation of PI3K and KRAS signaling pathways. Cross-species analyses and validation in human samples demonstrated that KIT expression is conserved in ECs from both sporadic and HHT2 bAVMs. Drug-repurposing analysis identified KIT as a top actionable target, and we showed that Kit is directly repressed by BMP9/ALK1/SMAD4 signaling. Pharmacological inhibition of KIT reduced angiogenic reprogramming and vascular malformations in vivo without affecting normal vasculature. These findings identify a pathogenic angiogenic EC state and position KIT signaling as a therapeutically actionable pathway in bAVMs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Département De Pharmacologie Et De Physiologie, Faculté de médecine, Université de Montréal, Montréal, Centre De Recherche CHU St. Justine, Montréal, Quebec, Canada.
- Centre De Recherche CHU St. Justine, Montréal, Quebec, Canada.
- Département De Biochimie, Faculté de médecine, Université de Montréal, Centre De Recherche CHU St. Justine, Montréal, Quebec, Canada.
- Department of Anatomy and Cell Biology, School of Biomedical Sciences, McGill University, Montréal, Quebec, Canada.
- Département De Pathologie Et Biologie Cellulaire, Faculté de médecine, Université de Montréal, Centre De Recherche CHU St. Justine, Montréal, Quebec, Canada.
- Department of Neurological Surgery, University of California, San Francisco, San Francisco, California, USA.
Förderung
- Canadian Institutes of Health Research
Zitieren
APA
Drapé, E., Carrier, L., Cagnone, G., Fuad, A. R. M., Bizou, M., Sanchez, D., Anquetil, T., Wang, J., Touzani Walali, H. D., Gopinadhan, A., van Vliet, P. P., Howard, J. P., Ibnat, M., Andelfinger, G., Winkler, E., Larrivée, B., & Dubrac, A. (2026). Targeting KIT prevents brain arteriovenous malformations driven by ALK1-deficient angiogenic endothelial cells. Journal of Clinical Investigation. https://doi.org/10.1172/jci197587
Vancouver
Drapé E, Carrier L, Cagnone G, Fuad ARM, Bizou M, Sanchez D, et al. Targeting KIT prevents brain arteriovenous malformations driven by ALK1-deficient angiogenic endothelial cells. Journal of Clinical Investigation. 2026. doi:10.1172/jci197587
BibTeX
@article{Drap2026,
author = {Drapé, Elise and Carrier, Lauranne and Cagnone, Gael and Fuad, Atik Rohmana Maftuhatul and Bizou, Mathilde and Sanchez, Damian and Anquetil, Typhaine and Wang, Jack and Touzani Walali, Halima Drissi and Gopinadhan, Adnan and van Vliet, Patrick Piet and Howard, Joel P and Ibnat, Mysha and Andelfinger, Gregor and Winkler, Ethan and Larrivée, Bruno and Dubrac, Alexandre},
title = {Targeting KIT prevents brain arteriovenous malformations driven by ALK1-deficient angiogenic endothelial cells},
journal = {Journal of Clinical Investigation},
year = {2026},
doi = {10.1172/jci197587}
}
EUVIMED